Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus.
The ability of dogs vaccinated with a live attenuated CPV type 2 (Nobivac Intervet) vaccine to resist challenge with a current CPV2c isolate was investigated. Six SPF beagle dogs were given the minimum recommended course of vaccination, comprising a single inoculation of vaccine (Nobivac Lepto+Nobivac Pi) at 8-10 weeks of age followed 3 weeks later with a parvovirus vaccine in combination with distemper, adenovirus and parainfluenza virus (Nobivac DHPPi) and a repeat leptospirosis vaccine. Six control dogs were kept unvaccinated. All animals were challenged orally with a type 2c isolate of CPV and monitored for clinical signs, virus shedding, white blood cell fluctuations and serological responses. All vaccinated dogs were fully protected; showing no clinical signs nor shedding challenge virus in the faeces, in contrast to control animals, which displayed all the typical signs of infection with pathogenic CPV and shed challenge virus in the faeces.
Spibey
N
N
Intervet UK Ltd, Walton Manor, Milton Keynes, UK. norman.spibey@intervet.com
Greenwood
N M
NM
Sutton
D
D
Chalmers
W S K
WS
Tarpey
I
I
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000097:blood; D004283:Dog Diseases / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D004285:Dogs; D007958:Leukocyte Count / Q000662:veterinary; D009500:Neutralization Tests / Q000662:veterinary; D010322:Parvoviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary* / Q000821:virology; D017993:Parvovirus, Canine / Q000276:immunology*; D014611:Vaccination / Q000662:veterinary*; D014613:Vaccines, Attenuated / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines